Member Info for RNmyS

I guess I’m too old or you youngsters are too young to remember the 145p to 98p drop we experienced after a presentation last summer.

Great spot Timster, Fran was also not previously listed as, "Senior Manager, Business Development for North America", her old description was just, "Senior Manager, Business Development"... Previously no "North America" reference. Good change to see, especially with her background.

This, along with the decision to switch the Chief Scientific Officer with the Chief Commercial Director does hint at a strong focus on commercialization. As with the partnerships page, there's always a reason for these changes, and if we are about to be releasing a world class test, our commercialization / business dev team will be vital.

This all changed over this past weekend (I only noticed as I had the previous version of the page still open in a separate tab)

David Wilson has now been moved up to the top of the page, next to Alastair Smith, on the "meet the team" section of the diagnostics page. While this move seems uninteresting, a conscious decision has been made by Avacta to elevate their Diagnostics Commercial Director.

See changes:
Old view: http://web.archive.org/web/20210208142648/https://avacta.com/diagnostics/
New: https://avacta.com/diagnostics/

Just sharing as an FYI.

Use this to avoid paywalls: https://github.com/iamadamdev/bypass-paywalls-chrome

Get a grip? huh? - I am just sharing my opinion Ndn, just as you have done.

Johnny, he *could have done. Immediately after his tweet the share saw a small spike, this has happened with many other tweets he mentions, however, in the case of Avacta, there are many wary investors who are expecting news at any time. His tweet *could have been a catalyst for others to start buying (I know several who bought into the spike) and or the MMs to say, okay we'll let this rise again thus pushing the sp.

https://amp.theguardian.com/world/2021/apr/15/rapid-covid-testing-in-england-may-be-scaled-back-over-false-positives

TL;DR: Current testing isn't accurate enough.

Even if it takes a while longer, a full sample study will allow us to provide evidence to support our s/s figures. It is and will be vital in showing that our tests work as intended, unlike the Innova crap.

.

Just as MN tweeted ( https://twitter.com/MylesMcNulty/status/1382696413214212101 ). Am pretty confident his tweet just triggered a load of buying which has driven up the price. It's v close I'm sure, but I doubt this is a leak.

Thank you for sharing Poirot, will take a look.

Gotcha, been a little distanced from this board recently, can't be long now..

Appears the product page is now live once again and updated: https://avacta.com/diagnostics/products/

Changes are timestamped here: https://avacta.com/sitemap_index.xml

Nothing to suggest 'more' delays. They have to RNS the upcoming investor presentation regardless of other news in the pipeline. For all we know we could have the s/s results by this time tomorrow.

It is usually a good thing to have diversity of thought but you seem to have an unhealthy distaste for this share. I will give you the benefit of the doubt here though and provide you with this, which I feel sums up any perceived delays nicely:

https://www.youtube.com/watch?v=wxmXQyVaNTU&t=795s&ab_channel=**********

If you want to bypass any payways, check out this extension, works with each of the main news outlets.
https://github.com/iamadamdev/bypass-paywalls-chrome

:)

Nothing wrong with that :)

wyn:

Some nice research there Sisu, I think we were all very interested with every aspect of that page while it was live, but it's also worth noting the, "Image for illustrative purposes only." message below the image.

https://webcache.googleusercontent.com/search?q=cache:YxXnzMciVHUJ:https://avacta.com/diagnostics/products/+&cd=1&hl=en&ct=clnk&gl=uk

It says below the image, "Image for illustrative purposes only.", so don't read into it

While this delay is frustrating, the importance of a larger sample study is simple, it will provide a strong evidence case to back up our s/s claims versus other companies who have cut corners and validated on much smaller sample sizes (look at Sona last year). We have all already seen that many of these claimed s/s results do not stand up to scrutiny as shown here: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32635-0/fulltext (Thanks you Timster for sharing).

If Alastair informs us of the results based on a sample of say 500+ people, even the likes of Deeks will have a hard time refuting the accuracy and use case of the AVCT LFT (I'm sure he still will though). While it's taking a little longer for us to receive these results, I'm sure it will be worth the wait.